Schrodinger, Inc. (SDGR)
| Market Cap | 6.32B |
| Revenue (ttm) | 100.90M |
| Net Income (ttm) | -20.09M |
| Shares Out | 66.34M |
| EPS (ttm) | -0.49 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $90.89 |
| Previous Close | $92.85 |
| Change ($) | -1.96 |
| Change (%) | -2.11% |
| Day's Open | 92.20 |
| Day's Range | 87.61 - 94.50 |
| Day's Volume | 793,134 |
| 52-Week Range | 26.60 - 94.50 |
The biotechnology exchange-traded fund SPDR S&P Biotech ETF (NYSE: XBI) is up around 50% in 2020 and Jefferies' managing director Michael Yee says the valuations are not only justified but sus...
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, presented preclinical data...
Schrödinger Inc. shares jumped about 8% in premarket trade Monday, after the company announced a drug discovery agreement with Bristol Myers Squibb Co. that could net it up to $2.7 billion in ...
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced a discover...
Schrödinger stock is almost at half the price since peaking in the summer. Stock dilution hurt investors, but the market is betting on its software growth.
Schrödinger, Inc. (SDGR) CEO Ramy Farid on Q3 2020 Results - Earnings Call Transcript
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced financial ...
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that membe...
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced it will pr...
NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced it will host a c...
Big Tech companies have been the hottest stocks on Wall Street all year, pre- and post-pandemic. But some experts think it's time for a new crop of dynamic up-and-comers in fields like virtual...
Schrodinger (SDGR) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Schrödinger, Inc. has exhibited a stock price slide since July, even as revenue growth continues above expectations.
Three great performing yet relatively unknown med-tech stocks with a high upside.
Schrödinger's computational platform integrates physics-based methods with machine-learning techniques to enable drug discovery and development of novel materials.
Schrödinger has an innovative computational platform that accelerates the discovery of new molecules for use in therapeutics and industrial materials.
Schrodinger (SDGR) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Schrödinger, Inc. (SDGR) CEO Ramy Farid on Q2 2020 Results - Earnings Call Transcript
SHANGHAI and NEWYORK, July 28, 2020 /PRNewswire/ -- Viva Biotech Holdings (1873.HK) and Schrödinger, Inc. (Nasdaq: SDGR) today announced a strategic collaboration to expand the reach of struct...
A company that can speed up drug discovery; one that is already partnering with the world’s 20 biggest drug companies and appears to be just scratching the surface of its potential.
Schrödinger, Inc. (SDGR) CEO Ramy Farid on Q1 2020 Results - Earnings Call Transcript
Schrodinger - Taking Drug Discovery To The 'Space Age'
The company continues to coast on a positive note from Citron Research.
1 hot IPO plus 1 comparison to Tesla equals 1/3 more stock value.
Notable activist short seller Andrew Left and his Citron Research firm said in a new report Schrodinger Inc (NASDAQ: SDGR) is the "most important IPO" in the past five years.
About SDGR
Schrödinger provides computational platform to accelerate drug discovery and materials design for biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. The company operates through two segments, Software and Drug Discovery. Its segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment develops a pipeline of preclinical and clinical drug discovery programs through its computat... [Read more...]
| Industry Health Information Services | IPO Date Feb 6, 2020 |
| CEO Dr. Ramy Farid | Employees 392 |
| Stock Exchange NASDAQ | Ticker Symbol SDGR |
Financial Performance
In 2019, Schrodinger's revenue was $85.54 million, an increase of 28.37% compared to the previous year's $66.64 million. Losses were -$24.57 million, -13.56% less than in 2018.
Analyst Forecasts
According to 4 analysts, the average rating for Schrodinger stock is "Buy." The 12-month stock price forecast is 91.00, which is an increase of 0.12% from the latest price.